Association of lncRNA PVT1 Gene Polymorphisms with the Risk of Essential Hypertension in Chinese Population

Table 4

Association between lncRNA PVT1 polymorphisms and EH risk in the north of China.

Models	Genotypes	Control, (%)	EH, (%)	Unadjusted OR (95% CI)	value	Adjusted OR (95% CI)	Adjusted value
rs10956390
Additive	CC	33 (22.8)	100 (38.0)	1.00 (reference)		1.00 (reference)
	CT	71 (48.3)	113 (43.0)	0.525 (0.321-0.860)	0.010	0.409 (0.221-0.757)	0.004
	TT	41 (28.3)	50 (19.0)	0.402 (0.228-0.712)	0.002	0.341 (0.168-0.693)	0.003
Dominant	CC	33 (22.8)	100 (38.0)	1.00 (reference)		1.00 (reference)
	CT/TT	112 (77.2)	163 (62.0)	0.480 (0.303-0.762)	0.002	0.384 (0.216-0.684)	0.001
Recessive	CC/CT	104 (71.7)	223 (81.0)	1.00 (reference)		1.00 (reference)
	TT	41 (28.3)	50 (19.0)	0.595 (0.370-0.957)	0.032	0.598 (0.333-1.072)	0.084
rs80177647
Additive	TT	124 (85.5)	194 (73.8)	1.00 (reference)		1.00 (reference)
	TA	19 (13.1)	63 (24.0)	2.119 (1.210-3.711)	0.009	1.535 (0.802-2.938)	0.196
	AA	2 (1.4)	6 (2.3)	1.918 (0.381-9.652)	0.430	0.734 (0.109-4.944)	0.751
Dominant	TT	124 (85.5)	194 (73.8)	1.00 (reference)		1.00 (reference)
	TA/AA	21 (14.5)	69 (26.3)	2.100 (1.226-3.596)	0.007	1.449 (0.775-2.710)	0.246
Recessive	TT/TA	143 (98.6)	257 (97.7)	1.00 (reference)		1.00 (reference)
	AA	2 (1.4)	6 (2.3)	1.669 (0.333-8.379)	0.534	0.664 (0.098-4.483)	0.674

OR: odd ratio; CI: confidence interval; EH: essential hypertension. Adjusted for age, gender, BMI, smoking history, FBG, and dyslipidemia.